Prelude Therapeutics (NASDAQ:PRLD) Issues Quarterly Earnings Results

Prelude Therapeutics (NASDAQ:PRLD) announced its earnings results on Monday. The company reported ($0.46) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.46), Zacks reports.

Prelude Therapeutics Stock Down 7.3 %

Prelude Therapeutics stock traded down $0.45 during midday trading on Wednesday, hitting $5.75. 142,454 shares of the company’s stock were exchanged, compared to its average volume of 80,070. The firm has a 50-day moving average of $4.61 and a two-hundred day moving average of $4.27. Prelude Therapeutics has a 12 month low of $1.66 and a 12 month high of $6.80.

Analyst Ratings Changes

Separately, Barclays cut Prelude Therapeutics from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective for the company. in a report on Thursday, June 20th.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.